December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Hagop Kantarjian: We review the evidence leading to Tagraxofusp approval as first in class CD123-directed drug which has changed the field of BPDCN
Apr 21, 2024, 21:27

Hagop Kantarjian: We review the evidence leading to Tagraxofusp approval as first in class CD123-directed drug which has changed the field of BPDCN

Hagop Kantarjian, Leukaemia professor and Chair at MD Anderson Cancer Center, shared on X:

“Tazgraxofusp is a first in class CD123 directed drug which has changed the field of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). We review the evidence leading to its approval, use in combos and newer CD123 agents.”

Additional information.
Source: Hagop Kantarjian/X


About OncoDaily 

OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.

OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.

The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we”.